Tryp Therapeutics Inc. TRYPF Archives - Page 6 of 8

MondayJul 26, 2021 1:20 pm

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Strategic Board Appointments

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced the appointment of Robin Carhart-Harris, Ph.D. as chairman of Tryp’s Scientific Advisory Board (“SAB”) and Daniel Clauw, M.D. as a new member of the SAB. Dr. Carhart-Harris initially joined Tryp’s SAB in February 2021 and has been instrumental in advising the company through the development of its Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”) program. Dr. Clauw is a world-leading expert in fibromyalgia and other nociplastic pain indications. “With today’s announcement, I would like to thank Dr. Robin…

ThursdayJul 22, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Preview Milestones for Novel Psychedelic Therapies in Investor Day Event

Tryp Therapeutics is a drug developer whose mission is to find novel solutions to conditions with otherwise unmet needs The company has distinguished itself by developing a synthetic oral psilocybin product that it aims to use in the treatment of chronic pain and eating disorder indications under its psychedelic medicine research program Tryp’s management team will address investors in a Fiscal Q3 review on July 29 that also serves as an opportunity to talk about upcoming milestones for the company Venture capital investment interest in psychedelic therapies has grown explosively from $1 million in 2017 to $329 million during the…

WednesdayJul 21, 2021 10:24 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), University of Michigan to Collaborate in Phase 2a Clinical Trial for Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced its plans to conduct a phase 2a clinical trial with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School. According to the update, the open-label trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia. The treatment is designed to leverage the neuroplasticity benefits of psilocybin to target nociplastic pain originating in the central…

FridayJul 16, 2021 1:44 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Agreement with University of Michigan for Testing of Latest Psychedelic Drug Candidate

San Diego-based Tryp Therapeutics is developing new drug candidates with the aim of treating medical conditions that currently have limited effective therapy Tryp has solidified an agreement with the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science to test synthetic psychedelic drug candidate TRP-8803 to advance its use in upcoming clinical trials The Company has also established an agreement with the University of Florida to test its lead drug candidate — TRP-8802 — for certain eating disorders Psychedelics are beginning to gain new respect and attention for addressing select neurological conditions as scientists,…

ThursdayJul 15, 2021 12:20 pm

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Upcoming Q3 Investor Day

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, will be hosting a third-quarter virtual Investor Day. The company has scheduled this event for July 29, 2021; it will begin at 9 a.m. PDT. Included on the event agenda will be a presentation by Tryp’s management team. The presentation will provide updates regarding the company’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program. The team will also discuss 2021 milestones. In addition, the agenda features a Q&A session. Tryp executives participating in the event include Greg McKee,…

ThursdayJul 08, 2021 1:00 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Similar Strategy as Leading Cannabis-Derived Compound Pharmaceutical Company

Jazz Pharmaceuticals’ acquisition of GW Pharma for $7.2 billion in February 2021 shows the massive potential of the drug development industry from naturally-derived compounds Tryp Therapeutics is following in the footsteps of GW with its innovative drug pipeline and the development of psilocybin-based compounds for the treatment of diseases with high unmet medical needs It is one of only a handful of companies moving into Phase 2a clinical trials with a psychedelic compound, and seeks to duplicate the success of GW As of 2020, the global biotech sector was valued at $753 billion. It is further projected to grow at…

WednesdayJul 07, 2021 10:07 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Strategic Collaboration with the University of Michigan

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced an agreement with the University of Michigan to perform research related to Tryp's Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”) program. According to the update, the collaboration is part of a series of upcoming bridging studies designed to expand Tryp's intellectual property portfolio for the company's novel TRP-8803 drug formulation compared with conventional oral formulations of synthetic psilocybin. The studies will also facilitate the advancement of TRP-8803 into Phase 2b clinical trials. “We are excited to initiate our…

FridayJul 02, 2021 10:19 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share its Drug Development Pipeline and the Company’s Progress in the Psych Investor Summit

Tryp Therapeutics will be participating in the second global Psych Investor Summit: Research and Development The virtual presentation is scheduled for July 7 from 11:50 a.m. to 12:50 p.m. EDT It will focus on the psychedelics industry, showcasing the latest research and development within the sector Mr. Greg McKee, Chairman and CEO of Tryp Therapeutics, will share information on the company, along with its drug development pipeline In an official statement dated June 24, 2021, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) confirmed that it would participate in the Psych Investor Summit: Research and Development. The virtual event, scheduled on Wednesday,…

ThursdayJul 01, 2021 12:18 pm

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Advance Psychedelic Medicine Program

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is partnering with pharmaceutical research companies that will provide support services for the development of its synthetic TRP-8802 psilocybin product. This is on top of a collaboration with pediatric eating disorders expert Jennifer Miller, M.D. of the University of Florida, who is directing the investigation/clinical trials of the product. Fluence, a psychedelic therapy educational platform, will provide design and training for the psychotherapeutic portion of Tryp’s upcoming clinical trials, while Clinlogix, a global novel pharmaceutical product contract research organization, will provide support services. “Tryp announced on May 25 that global pharmaceutical contract development and…

FridayJun 25, 2021 11:41 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Discusses Its Vision for Addressing Patient Needs

In 2021, Tryp Therapeutics plans on expanding its academic collaborations It also plans to initiate Phase 2a clinical studies for its synthetic psilocybin drug product as a way to determine efficacy in patient populations Tryp Therapeutics is constantly working on identifying alternative and better ways to control doses and control the patient experience in their dissociative state, mainly through innovations in drug formulation and delivery A primary objective of the administration of psilocybin is to increase the neuroplasticity of the brain Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently shed light on its operations and the vision that it has both…

Site Search

Company Search

Tag: Tryp Therapeutics Inc. TRYPF